$ABEO

ABEONA THERAPEUTICS INC.

Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its commercial product, ZEVASKYN, is an autologous gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. Abeona manufactures ZEVASKYN at its Cleveland, Ohio facility and commercializes it through qualified treatment centers; as of March 2026, it has activated 4 centers. Its development portfolio includes AAV-based gene therapy programs for ophthalmic diseases using AIM capsids, including programs for X-linked retinoschisis, Stargardt disease and autosomal dominant optic atrophy. Abeona makes money by commercializing ZEVASKYN and through licensing arrangements that provide for upfront, milestone and royalty payments. It has licensed AAV204 to Beacon Therapeutics for selected gene or disease targets and has out-licensed programs for Sanfilippo syndrome type A and Rett syndrome. Abeona is headquartered in Cleveland, Ohio.

2
0
0
$34K
—
Charles Faith L.
0%
See all $ABEO insider activity →

Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands

Abeona Therapeutics (NASDAQ:ABEO) plans a new Phase 3 trial for ABO-801, with $135M in cash and additional funding expected to cover development costs. ZEVASKYN, its FDA-approved gene therapy, has treated 15 patients, with 8 treatment centers active in the U.S. The company aims to expand these centers and is monitoring wound-healing observations.

ABEO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ABEO (ABEONA THERAPEUTICS INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent ABEO coverage spans financial news, earnings and mergers & acquisitions.

In the last 30 days, ABEO insiders filed 1 SEC Form 4 transaction — 1 purchase ($34K) and no sales. The most active reporter was Charles Faith L. with 1 filing.

What's driving ABEO

  • Small insider purchase with limited market impact.

    SEC EDGAR · Nov 16, 2026

  • HC Wainwright & Co. kept its Buy rating on Abeona Therapeutics but reduced its price target to $18 from $20, representing a 10% decrease. The new target suggests a 682.6% upside from the Nov 11 close of $2.30.

    tradingview.com · Nov 12, 2026

  • The Phase 3 announcement adds upside potential as investors price in future data readouts.

    finance.yahoo.com · Nov 12, 2026

  • Potential upside as capacity increase and cash resources may improve margins; however short-term revenue may be constrained by shutdown.

    finance.yahoo.com · Nov 9, 2026

  • Earnings beat is outweighed by heightened execution risk and cash‑burn concerns, likely keeping pressure on the share price.

    investing.com · Nov 9, 2026

AlphAI scores every news story that mentions ABEO with an AI model for sentiment and relevance, and aggregates insider trades from ABEONA THERAPEUTICS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ABEO

Score

Abeona Therapeutics Inc (ABEO) (Q3 2026) Earnings Call Highlights: ZivaSkin Revenue Jumps

Abeona Therapeutics reported an 18% revenue jump for ZivaSkin. CEO Vish Seshadri discussed plans to expand manufacturing capacity to 10 patients/month by mid-2027. CFO Joe Vizana expects 85%-90% gross margins at full capacity. ABO-801, an oral disintegrating tablet for EoE, is positioned as a convenient option. Abeona aims for a single Phase 3 trial for ABO-801, with estimated costs of $50M-$60M, covered by current cash and future sales.

$ABEOMedEarnings

Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Third Quarter 2026 Financial Results and ZEVASKYN ® Commercial Progress – Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network ex

$ABEOHighM&A· acquirer · $20M · completed

ABEONA THERAPEUTICS INC. (ABEO): Completion of Acquisition or Disposition of Assets

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Abeona Therapeutics ® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement - Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations – – ABO-801 acqui

James Russell Pushes for Changes at Abeona Therapeutics with 6.1% Stake

James Russell's trust reported a 6.1% stake in Abeona Therapeutics (ABEO) and plans to push for board and leadership changes. Russell met with directors, citing concerns about operations and governance. He may nominate candidates or oppose incumbents at the 2027 annual meeting. The trust spent $17.8 million on shares, including $3.7 million recently.

Related tickers